1
|
Tan D, Du X, Tang J, Liu H, Li M, Kang J, Li X, Li Y, Luo Y, Wang Q, Gu X, Zhao Z, Fu X, Chen X. Factors associated with the SARS-CoV-2 immunoglobulin-G titer levels in convalescent whole-blood donors: a Chinese cross-sectional study. Sci Rep 2024; 14:6072. [PMID: 38480826 PMCID: PMC10937670 DOI: 10.1038/s41598-024-56462-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2024] [Accepted: 03/06/2024] [Indexed: 03/17/2024] Open
Abstract
Blood transfusions from convalescent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infected patients could be used to treat patients with severe infections or immunocompromised patients. However, it is necessary to select the optimal donors to maximize the utilization of resources. In this study, we investigated the associations among body mass index (BMI), tobacco smoking, exercise frequency and duration, and alcohol consumption with the SARS-CoV-2 immunoglobulin-G (IgG) antibody titer levels with in the Chinese convalescent blood donor population. Here we show that BMI, smoking habits, and exercise frequency appear to be predictive factors for IgG levels in convalescent male blood donors. However, these variables were not observed as predictive of IgG levels in female convalescent blood donors. The findings could be used to optimize the screening for potential blood donors to treat immunocompromised or severely ill COVID-19 patients.
Collapse
Affiliation(s)
- Donglin Tan
- Department of Blood Processing, Chengdu Blood Center, Chengdu, 610041, Sichuan, China
| | - Xinman Du
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Jingyun Tang
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Humin Liu
- Department of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Meng Li
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Jianxun Kang
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Xiaochun Li
- Department of Blood Processing, Chengdu Blood Center, Chengdu, 610041, Sichuan, China
| | - Ying Li
- Department of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Yue Luo
- Blood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Qing Wang
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Xiaobo Gu
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Zonghan Zhao
- Department of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China
| | - Xuemei Fu
- Department of Blood Processing, Chengdu Blood Center, Chengdu, 610041, Sichuan, China.
| | - Xue Chen
- Department of Blood Processing, Chengdu Blood Center, Chengdu, 610041, Sichuan, China.
| |
Collapse
|
2
|
Transthyretin-mediated protein and peptide oligomerization for enhanced target clustering. Emerg Top Life Sci 2021; 5:665-668. [PMID: 34282847 DOI: 10.1042/etls20210028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 06/24/2021] [Accepted: 06/28/2021] [Indexed: 01/24/2023]
Abstract
Advances in cancer research have led to the development of new therapeutics with significant and durable responses such as immune checkpoint inhibitors. More recent therapies aim to stimulate anti-tumor immune responses by targeting the tumor necrosis factor (TNF) receptors, however this approach has been shown to require clustering of receptors in order to achieve a significant response. Here we present a perspective on using transthyretin, a naturally occurring serum protein, as a drug delivery platform to enable cross-linking independent clustering of targets. TTR forms a stable homo-tetramer with exposed termini that make TTR a highly versatile platform for generating multimeric antibody fusions to enable enhanced target clustering. Fusions with antibodies or Fabs targeting TRAILR2 were shown to have robust cytotoxic activity in vitro and in vivo in colorectal xenograft models demonstrating that TTR is a highly versatile, stable, therapeutic fusion platform that can be used with antibodies, Fabs and other bioactive fusion partners and has broad applications in oncology and infectious disease research.
Collapse
|